Leerink Partners Maintains Outperform on CVS Health, Lowers Price Target to $112

Benzinga Newsdesk www.benzinga.com Negative 93.7%

Neg 93.7% Neu 0% Pos 0%

Leerink Partners analyst Michael Cherny maintains CVS Health (NYSE:CVS) with a Outperform and lowers the price target from $119 to $112.